122 related articles for article (PubMed ID: 36963882)
21. Genetic factors help explain the variable responses of young children with cystic fibrosis to vitamin D supplements.
Lai HJ; Song J; Lu Q; Murali SG; Gajapathy M; Wilk BM; Brown DM; Worthey EA; Farrell PM;
Clin Nutr ESPEN; 2022 Oct; 51():367-376. PubMed ID: 36184229
[TBL] [Abstract][Full Text] [Related]
22. Vitamin E supplementation in people with cystic fibrosis.
Okebukola PO; Kansra S; Barrett J
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD009422. PubMed ID: 32892350
[TBL] [Abstract][Full Text] [Related]
23. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.
Hurley MN; Smith S; Forrester DL; Smyth AR
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD008037. PubMed ID: 32671834
[TBL] [Abstract][Full Text] [Related]
24. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
25. Dornase alfa for cystic fibrosis.
Yang C; Montgomery M
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001127. PubMed ID: 33735508
[TBL] [Abstract][Full Text] [Related]
26. Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis.
Lai HJ; Chin LH; Murali S; Bach T; Sander D; Farrell PM;
Pediatr Pulmonol; 2022 Apr; 57(4):935-944. PubMed ID: 35018747
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Rosenfeld M; Rayner O; Smyth AR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD001912. PubMed ID: 32997797
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.
Sanders DB; Bittner RC; Rosenfeld M; Redding GJ; Goss CH
Pediatr Pulmonol; 2011 Apr; 46(4):393-400. PubMed ID: 20967845
[TBL] [Abstract][Full Text] [Related]
29. Inhaled mannitol for cystic fibrosis.
Nevitt SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008649. PubMed ID: 29424930
[TBL] [Abstract][Full Text] [Related]
30. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis.
McIlwaine M; Button B; Dwan K
Cochrane Database Syst Rev; 2015 Jun; (6):CD003147. PubMed ID: 26083308
[TBL] [Abstract][Full Text] [Related]
31. Oscillating devices for airway clearance in people with cystic fibrosis.
Morrison L; Milroy S
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD006842. PubMed ID: 32352564
[TBL] [Abstract][Full Text] [Related]
32. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
33. Recombinant growth hormone therapy for cystic fibrosis in children and young adults.
Thaker V; Carter B; Putman M
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD008901. PubMed ID: 30557452
[TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of stoss therapy in children with vitamin D deficiency.
Tannous P; Fiscaletti M; Wood N; Gunasekera H; Zurynski Y; Biggin A; Kilo T; Hayes E; Munns C
J Paediatr Child Health; 2020 Jan; 56(1):81-89. PubMed ID: 31136042
[TBL] [Abstract][Full Text] [Related]
35. Dornase alfa for cystic fibrosis.
Yang C; Montgomery M
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001127. PubMed ID: 30187450
[TBL] [Abstract][Full Text] [Related]
36. Vitamin E supplementation in people with cystic fibrosis.
Okebukola PO; Kansra S; Barrett J
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD009422. PubMed ID: 28262916
[TBL] [Abstract][Full Text] [Related]
37. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
[TBL] [Abstract][Full Text] [Related]
38. Oscillating devices for airway clearance in people with cystic fibrosis.
Morrison L; Innes S
Cochrane Database Syst Rev; 2017 May; 5(5):CD006842. PubMed ID: 28471492
[TBL] [Abstract][Full Text] [Related]
39. Vitamin D intervention in preschoolers with viral-induced asthma (DIVA): a pilot randomised controlled trial.
Jensen ME; Mailhot G; Alos N; Rousseau E; White JH; Khamessan A; Ducharme FM
Trials; 2016 Jul; 17(1):353. PubMed ID: 27456232
[TBL] [Abstract][Full Text] [Related]
40. Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study.
Pincikova T; Nilsson K; Moen IE; Karpati F; Fluge G; Hollsing A; Knudsen PK; Lindblad A; Mared L; Pressler T; Hjelte L;
Eur J Clin Nutr; 2011 Jan; 65(1):102-9. PubMed ID: 20859300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
